Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brinzolamide + brimonidine
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
**Brinzolamide + brimonidine** is a fixed-dose ophthalmic suspension combining brinzolamide, a carbonic anhydrase inhibitor, with brimonidine, a selective alpha-2 adrenergic receptor agonist. Marketed most prominently as **Simbrinza**, it lowers elevated intraocular pressure by reducing aqueous-humor production; brimonidine also increases uveoscleral aqueous outflow. It is approved for reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension and provides a beta-blocker-free multidrug option for topical glaucoma management.
- Brand names
- Azopres BRBrinmide-BBrinzobrimSimbrinza
- Other names
- BBFCbrimonidine + brinzolamidebrimonidine tartrate + brinzolamidebrinz/brimbrinzolamide + brimonidinebrinzolamide + brimonidine tartratebrinzolamide and brimonidinebrinzolamide/brimonidinebrinzolamide/brimonidine ophthalmicbrinzolamide/brimonidine tartratefixed-combination brinzolamide/brimonidine
02
Targets
ADRA2A (α2A)CA2 (Carbonic Anhydrase 2)
Beyond the preview
Go deeper on brinzolamide + brimonidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brinzolamide + brimonidine.